Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Panel2: Working with the Current [email protected] Academy of SciencesWashington, D.C.
Increasing trust through open science
“At GSK we recognize that great science happens outside as well as inside our walls. In fact, we see collaborations with other researchers as an important component of our R&D activities, complementing our in-house efforts and advancing scientific understanding in key areas and facilitating the rapid discovery and development of new medicines for patients.”
From trustinscience.gsk.com
DDW Open Innovation Approach
4
Investment in DDW to act as a catalyst and stimulate research outside of GSK
22nd October 2013D34DDW
1. Providing access to our
know-how and resources via
the open lab
2. Sharing our data with the
research community – “open
source”
3. Being more flexible with
our IP
Three key elements
K. Guy, R. Gilbertson (St. Jude CRH)• Neurosphere models of rare pediatric cancers
The Kinome Test Set: > 100 collaborations
V. Lemmon, J. Bixby (U. of Miami)• High content imaging in primary rat neurons
6 nM GW779439X
Examples
External funding enabled by GSK PKIS
Category Investigator Focus Source
<$0.1M Adrienne Flanagan, UCL Chordoma Sarcoma UK
John de Groot, MD Anderson Glioblastoma TxSACT
Andrew Tobin, U of Leicester Malaria MRC
$0.1-1.0 M Milica Radisic, U of TorontoBeating cardiacorganoids
CIHR
Steve Pollard , UCL Neuroblastoma CRUK
Nanosyn Kinase screening Nanosyn/SGCCIHR: Canadian Institute for Health Research
TxSACT: Texas Screening Alliance for Cancer Therapeutics CRUK: Cancer Research UK
Category Investigator Focus Source
<$0.1MBin Teh(Natl. U of Singapore)
Bile duct cancer Public
>$1.0MMultiparty (U of Campinas, Brazil)
Kinome PPP Public
Pending applications:
Funded applications:
The DPAc Model and Organization Are Unique
Collaborative Invention
Shared Ownership
Risk Embracing
Research Milestones
Candidate Clinical NMEs
POCs and C2MD
A discovery team with the remit to build a rolling pipeline of 13
candidate medicines, with an academic partner at the center of each project.
A collaborative approach from GSK
Build integrated partnerships that can translate
innovative research into medicines that benefit patients.
GSK has capabilities and expertise which will help
progress the project to the next milestone.
A path to identification of a drug molecule can be defined.
Target knowledge suggests that a drug-like molecule can
be generated.
Academic partner has know-how and/or expertise essential to
progressing the target which is not (readily) found elsewhere.
Specific drug target identified, and some understanding
of type of pharmacology desired.
What Are We Looking For?
A coherent and supportable hypothesis that modulation of
target will produce a physiological effect which will be of
therapeutic benefit to particular patients.
Requirement
for GSK
contribution
Tractability
(Exclusive)
enabling
expertise
Target
defined
Clear
therapeutic
hypothesis
Academic researchers who:
• Want to be involved in turning their innovative research
into medicines
• Will contribute their own effort and resources to making
projects work
• Have recognised expertise in their chosen field
• Bring something unique to the collaboration
Who is best suited for DPAc ?
Managing the relationship
• A co-authored and detailed work plan creates a framework to
promote rapid project initiation and execution
• Working together – Joint Research Committee
• Joint investment of time/energy/resource to progress the
project at both partner sites
• Strong interactive relationships between project team
• Equitable approach to IP
– Academic will receive commercial rights if GSK terminates the collaboration
How these new projects operate
Collaborative partnerships focussed on drug discovery
Starts at any point from initiation of early screening to late lead optimisation
Considers any disease area
Operates in any geography
Looks for a complementary match of skills where GSK can make a positive
contribution to success
This isn’t
✗Support for exploratory work
✗Focus on technology platforms
✗Broad multi-project collaborations
✗An open ended funding stream
Screening
Chemistry
Value of GSK
contribution$
Typical GSK activities
Assay Feasibility
Tool GenerationAssay Development
Screening
Chemistry
DMPK
Chemistry
DMPK
Safety
Pharmacy
$ $$ $$$ $$$
Assay
Dev
Target
Feasibility
Lead
ID
Early
LO
Late
LO
Pre-
ClinicalFTIH PhIIa PhIIb PhIII
Launch
Lead
Identification
Late Lead
OptimizationEarly Lead
Optimization
Assay
Development
Target
Feasibility
Drug Discovery
Initiated
Screen
Initiated
Lead Identified
In Vitro
Candidate
Selection
Lead Identified
In Vivo
Reagent Generation
Value research
support & reward
Physiological AssaysAssay Development
Typical academic activities
Physiological Assays
In Vitro and In VivoPhysiological Assays
In Vivo Models
$ $ $ $ $$+ downstream milestones
and royalties
Shared Activities Between Academia and GSK
We Have Established Nine Rewarding Partnerships
Developing treatments
for Recessive Dystrophic
Epidermolysis Bullosa and
other genetic diseases
Professor
Irwin McLean,
University of
Dundee
Mark
Bamford,
GSK
Preventing Multiple
Organ Failure in Severe
Acute Pancreatitis
Mr Damian
Mole,
University of
Edinburgh
John
Liddle,
GSK
Stabilisers of Transthyretin
as a treatment for
Transthyretin Amyloidosis
Professor Sir
Mark Pepys,
University
College of
London
Duncan
Holmes,
GSK
A disease modifying
approach to the
treatment of
Huntington’s Disease
Professor
Susann
Schweiger,
University of
Dundee
Iain
Uings,
GSK
Treating a1-Antitrypsin
Deficiency using small
molecule stabilisers
Professor
David
Lomas,
University of
Cambridge
Andy
Brewster,
GSK
Topical Therapy for
Netherton Syndrome,
Rosacea and Atopic
Dermatitis
Professor
Alain
Hovnanian, Paris
Descartes
University
John
Liddle,
GSK
We Have Established Nine Rewarding Partnerships
Progression through “Research Events”
already met in several projects
Professor
Roger
Cone
Dennis
Lee,
GSK
Prevention of DUX4-
mediated muscle atrophy
for treatment of
facioscapulohumeral
muscular dystrophy Professor
Stephen
Tapscott
Jon
Collins,
GSK
Modulators of MC4R for
treatment of obesity
Dual potentiator-
correctors of F508del
CFTR For Cystic Fibrosis
Professor
Christine
Bear
Jakob Busch-
Petersen,
GSK
Discovery Fast Track Competition
• For the first time, GSK will open access to its internal screening
capability—and industrialize a novel discovery concept posed by U.S.
and Canadian academic institutions
• Promising results may lead to an opportunity for the academic
institution and GSK to collaborate via the Discovery Partnerships for
Academia (DPAc) team
• The researcher provides a novel drug development concept that may include
assay protocols, tools, reagents and models
• GSK contributes an established capability to scale up and industrialize
assays and data analysis
How Does Discovery Fast Track Work?
70 institutions participated and 47% were new to DPAc
17
Surprisingly, all but one of the winners are on the East Coast…
We received 142 applications from 70 institutions
Graphical depiction of states participating in the US (blue)
Applications from 26 US States and 4 Canadian Provinces
10,589 hits to the website
14 of the Top 25 US Research
Universities applied,
of those four winners were
selected
Winners represented a range of therapeutic areas
18
Distribution of all proposals matched well with TA funded research in academia
Distribution of all proposals matched well
with TA funded research in academia
• Finalists and winners crossed a variety
of therapeutic areas
We Have Selected Eight Fast Track Winners
The selected scientists will collaborate
with GSK to rapidly screen and identify
novel compounds to test their promising
hypotheses.
Professor
Myles
Akabas
Patrick
Eidam,
GSK
A novel approach for
an anti-microbial
agent class of
antibiotic for gram
negative bacteria Professor
Sarah
Ades
Dennis
Lee,
GSK
A novel approach for
new treatments for
malaria
New compounds
for new
treatments of
LeishmaniasisProfessor
Lauren
Brown
Debra
Peattie,
GSK
Professor
Scott
Schaus
A novel approach for
the design of
antibiotics to
overcome clinical
resistance Professor
Rahul
Kohli
Katherine
Widdowson
GSK
Professor
Jim
McKerrow
We Have Selected Eight Fast Track Winners
The winning projects show clear
opportunities to deal with important
unmet medical needs.
Professor
Deborah
O’Brien
Jon
Collins,
GSK
A novel approach for
new treatments for
iron overload diseases
Professor
Richard
Leduc
Jakob Busch-
Peteresen,
GSK
A novel approach to
regulation of male
fertility
A novel approach for
new treatments for
metastatic epithelial
cancers
Professor
John
Sondek
Andy
Pope,
GSK
Winner wishes to
remain anonymous
Winner chooses to
remain anonymous
Dennis YamashitaGSK
DPAc: Who we are
Duncan Holmes European Head
LHR
Jon CollinsChemistry , RTP
David ParryBiology,, SAN
Pearl HuangBiologist and Global Head. PHL
Mark BamfordChemistry, LHR
Iain UingsBiologist, LHR and SAN
John LiddleChemistry, LHR
Andy PopeChemistry, PHL
Dennis LeeChemistry , PHL
Jakob Busch-Petersen
Chemistry , PHL
Ann WalkerChemist. LHR
Dennis YamashitaChemistry, BOS
Jeremy GriggsBiology, LHR
Katherine WiddowsonChemistry, SAN
Debra PeattieBiology,, BOS
Patrick EidamChemistry , Esprit
Stephane HuetBiology, CDG
Danuta MossakowskaBiology, LHR
A dedicated team of scientists,
each of whom have a proven track
record in drug discovery
Your gateway to GSK’s global
expertise and resources
Andy BrewsterRespiratory Chemistry, LHR
? ?